These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 22486070

  • 1. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
    Käypä hoito suosituksen päivitystiivistelmä.
    Duodecim; 2012; 128(5):539-40. PubMed ID: 22486070
    [Abstract] [Full Text] [Related]

  • 2. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA.
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [Abstract] [Full Text] [Related]

  • 3. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM, Earls MF.
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [Abstract] [Full Text] [Related]

  • 4. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R, Hodgkins P, Meijer W.
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [Abstract] [Full Text] [Related]

  • 5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 6. Improving decision making in the treatment of ADHD.
    Vitiello B.
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G, Newcorn JH.
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [Abstract] [Full Text] [Related]

  • 8. Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.
    Jensen PS.
    Am J Manag Care; 2009 May; 15(5 Suppl):S129-40. PubMed ID: 19601688
    [Abstract] [Full Text] [Related]

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 10. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 11. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB, Chae S, Patel A, Steinberg-Epstein R.
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [Abstract] [Full Text] [Related]

  • 12. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [Abstract] [Full Text] [Related]

  • 13. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML, American Academy of Pediatrics Committee on Quality Improvement, American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder.
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [Abstract] [Full Text] [Related]

  • 14. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
    Isaksson J, Hogmark Å, Nilsson KW, Lindblad F.
    Psychiatry Res; 2013 Oct 30; 209(3):740-1. PubMed ID: 23850434
    [Abstract] [Full Text] [Related]

  • 15. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P, Hsu HY, Chiou SS, Chao MC.
    Aust N Z J Psychiatry; 2007 Dec 30; 41(12):998-1004. PubMed ID: 17999272
    [Abstract] [Full Text] [Related]

  • 16. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
    Hodgkins P, Sasané R, Meijer WM.
    Clin Ther; 2011 Feb 30; 33(2):188-203. PubMed ID: 21497704
    [Abstract] [Full Text] [Related]

  • 17. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb 30; 19(105):5-8. PubMed ID: 20455329
    [Abstract] [Full Text] [Related]

  • 18. [Better health care for children and adolescents with attention deficit hyperactivity disorder].
    Klasen H, Verhulst FC.
    Ned Tijdschr Geneeskd; 2005 Jul 30; 149(31):1723-5. PubMed ID: 16114286
    [Abstract] [Full Text] [Related]

  • 19. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H.
    Psychiatr Danub; 2009 Sep 30; 21(3):330. PubMed ID: 19794351
    [No Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M, Munda B, Svab V, Locatelli I.
    J Affect Disord; 2015 Jun 01; 178():149-59. PubMed ID: 25813457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.